Despite significant advancements in GBM management, RT continues to face inherent limitations, primarily due to diffuse tumor infiltration and intrinsic radioresistance, often driven by specific molecular alterations like EGFR amplification, MGMT methylation, and TERT promoter mutations, alongside challenges from the immunosuppressive microenvironment and cancer neuroscience. This evidence concerns the gene MGMT and glioblastoma.